FDA rebuts criticism of government plan to set ADI of ractopamine
Taipei, April 22 (CNA) An allegedly proposed acceptable daily intake (ADI) of the leanness-enhancing drug ractopamine, which was criticized by several consumer groups Sunday, is just a consensus reached in a food safety evaluation meeting, Food and Drug Administration (FDA) Director-General Kang Jaw-jou said that day.
Access to articles dating back more than six months is not available free of charge. You can gain access by becoming a paid Focus Taiwan member.
※This website's content, including but not limited to text, images and video, cannot be reproduced, retransmitted or publicly broadcast without the authorization of CNA.